RA Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
Other funds holding AVDL
RI
ACA
VC
PC
BIP
CAC
GJL
GTC
PVI
RA Capital Management's AVDL Position: Q3 2020 in Review
RA Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 3,126,131 shares — an estimated $25.3M sold.
RA Capital Management first reported a position in AVDL in Q2 2020 and held it in 1 quarter. The position peaked at $25.3M in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.
- RA Capital Management reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
- RA Capital Management sold 3,126,131 Avadel Pharmaceuticals shares in Q3 2020, an estimated $25.3M.
- RA Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2020 and held it in 1 quarter.
- RA Capital Management's Avadel Pharmaceuticals position peaked at $25.3M in Q2 2020.
- 79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.
Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.